Fapon Highlights Local Manufacturing Solutions and Recombinant QC Materials at MEDICA 2026
Düsseldorf, November 19, 2026 – Fapon, a globally leading life sciences organization, has concluded its participation in MEDICA 2026, held from November 16 to 19 in Düsseldorf. At the show, the company showcased its Local Manufacturing Solutions and comprehensive IVD portfolio, highlighting how full-chain technology transfer, integrated diagnostic solutions and reliable raw material supply help IVD manufacturers strengthen local production capabilities and address evolving regional market needs.

At the exhibition, Fapon highlighted its Local Manufacturing Solutions, covering chemiluminescence immunoassay (CLIA), ELISA, clinical biochemistry, point-of-care testing (POCT) and molecular diagnostics (MDx). Through flexible collaboration models, Fapon provides full-chain technology transfer and localization services, covering core raw materials, bulk reagents, custom development, manufacturing and registration support. By combining technical know-how, reagent formulation and manufacturing expertise, Fapon helps partners establish or expand local IVD production capabilities, supporting the journey from assay development to local production and commercialization.
In addition to its localization services, Fapon showcased its one-stop IVD solutions, integrating IVD raw materials, reagent services and open-system instruments. With capabilities spanning antibody discovery, process development, reagent formulation and customization, Fapon supports diagnostic manufacturers at every stage of product development and manufacturing. Its blood-based Alzheimer's disease (AD) testing solutions show the same capability: they provide raw materials and bulk reagents for key biomarkers including p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP and NfL to support the development of blood-based AD assays. These capabilities give partners the technical and product support they need to develop and expand their diagnostic portfolios.

Another key highlight was Fapon's recombinant quality control (QC) and calibrator raw materials, developed to support consistent assay performance and reliable supply. Using recombinant expression technology, these materials help mitigate supply variability and biosafety risks associated with natural-source materials while supporting high lot-to-lot consistency.
In application evaluations, RF dilution linearity reached an R² of 0.9989, and clinical comparison testing showed an R² of 0.9924, indicating strong linearity and correlation. Production batches can be produced at working volumes of 0.8 L, 2 L, 6 L or 60 L in vessels up to 200 L, with batch size set according to customer demand, quarterly production cycles and available inventory supporting dependable supply. Fapon's AEO-certified status and overseas warehouses further strengthen global delivery capabilities. The portfolio covers key diagnostic markers including RF, CRP, CK-MB, HIV/HIV-P24, HBV and ToRCH, supporting clinical biochemistry, CLIA, ELISA and POCT applications.

With 25 years of experience in the IVD industry, more than 1,400 patent applications and partners in over 70 countries and regions, Fapon continues to advance diagnostic innovation and global collaboration. Through its integrated technology capabilities, comprehensive product portfolio and localization-focused services, Fapon is committed to helping partners accelerate diagnostic development and strengthen local IVD manufacturing.
At the show, Fapon engaged with IVD manufacturers and partners to explore collaboration opportunities and discuss their diagnostic development needs.
For further information or to discuss collaboration opportunities, please contact market@fapon.com.

About Fapon
Fapon, a globally leading life sciences organization, is redefining the R&D paradigm in diagnostics and therapeutics through a cutting-edge “AI-driven + a closed loop of dry and wet experiments” model. This approach significantly accelerates novel biomarker/target discovery and translation. The company has established an integrated business structure that combines AI-powered innovative discovery, one-stop diagnostic solutions and novel therapies. Its products and services cover the full spectrum of health management across the entire lifecycle, accelerating the development of precision medicine.
Follow us on LinkedIn (Fapon) or visit us at https://en.faponbiotech.com/